Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomized, phase 3 trial
The Lancet Nov 28, 2019
Heijerman HGM, McKone EF, Downey DG, et al. - In this phase 3, multicentre, randomized, double-blind, active-controlled trial of elexacaftor in combination with tezacaftor plus ivacaftor conducted at 44 sites in four countries of 113 individuals with cystic fibrosis homozygous for the F508del mutation, aged 12 years or older with stable disease, and with a percentage prognosticated forced expiratory volume in 1 of 40–90%, inclusive, experts ascertained the efficiency and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in individuals with cystic fibrosis homozygous for the F508del mutation. In comparison with tezacaftor plus ivacaftor alone, in the lives of persons with cystic fibrosis who are homozygous for the F508del mutation, a clinically strong advantage and a favorable safety profile by elexacaftor plus tezacaftor plus ivacaftor along with the potential to result in transformative developments was given.
Go to Original
Sign-up to continue reading. It is free & takes less than 2 mins
-
45 lakhs+ doctors trust M3 globally
-
Free & unlimited access to original articles and quizzes
-
Secure: we never sell your data
Quiz
Topic: General medicine, Family medicine
Risk reduction of fractures in postmenopausal women with severe osteoporosis is significantly greater with:
Sign up with M3 India to try daily quizzes and take part in competitions
Try M3 India / Log InWeekly competition with peers

Why join our Market Research Panel?
- 10K+ Doctors participated in 40+ Indian and Global studies in 2018
- Average honorarium per study was Rs. 1,600 and total honoraria as high as Rs. 12,000 was earned by a Doctor
Doctors' Testimonials
This article is only available to members. Are you a doctor? Click here to signup for free.